Β-lactamases: Difference between revisions

From IDWiki
Β-lactamases
No edit summary
Line 1: Line 1:
= Definition =
= Extended-spectrum beta-lactamase (ESBL) =

== Definition ==


* Bacteria containing a plasmid that codes for an extended-spectrum beta-lactamase (ESBL)
* Bacteria containing a plasmid that codes for an extended-spectrum beta-lactamase (ESBL)
* Most common with ''Escherichia coli'' and ''Klebsiella''
* Most common with ''Escherichia coli'' and ''Klebsiella''


== Classification ==
= Classification =


* Class A
* Class A
Line 17: Line 15:
** Common in ''Citrobacter'', ''Serratia'', and ''Enterobacter''
** Common in ''Citrobacter'', ''Serratia'', and ''Enterobacter''


== Management ==
= Management =


* Antibiotic therapy tailored to the resistance pattern
* Antibiotic therapy tailored to the resistance pattern
* Carbapenems, aminoglycosides, fluoroquinolones, and Septra typically work well
* Carbapenems, aminoglycosides, fluoroquinolones, and Septra typically work well

[[Category:Antibiotics]]

Revision as of 00:13, 15 August 2019

Definition

  • Bacteria containing a plasmid that codes for an extended-spectrum beta-lactamase (ESBL)
  • Most common with Escherichia coli and Klebsiella

Classification

  • Class A
    • Constitutively expressed plasmid
    • Most common ESBL in Gram-negative bacteria
    • Resistance to 2nd and 3rd generation cephalosporins
    • Common in E. coli, Klebsiella, and Proteus spp.
  • Class C
    • Inducible AmpC gene present in the genome
    • Common in Citrobacter, Serratia, and Enterobacter

Management

  • Antibiotic therapy tailored to the resistance pattern
  • Carbapenems, aminoglycosides, fluoroquinolones, and Septra typically work well

References

  1. ^  R. Cantón, M.I. Morosini, O. Martin, S. de la Maza, E. Gomez G. de la Pedrosa. IRT and CMT β-lactamases and inhibitor resistance. Clinical Microbiology and Infection. 2008;14:53-62. doi:10.1111/j.1469-0691.2007.01849.x.